430 related articles for article (PubMed ID: 31996409)
1. Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice.
Sugahara M; Tanaka S; Tanaka T; Saito H; Ishimoto Y; Wakashima T; Ueda M; Fukui K; Shimizu A; Inagi R; Yamauchi T; Kadowaki T; Nangaku M
J Am Soc Nephrol; 2020 Mar; 31(3):560-577. PubMed ID: 31996409
[TBL] [Abstract][Full Text] [Related]
2. The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease.
Hasegawa S; Tanaka T; Saito T; Fukui K; Wakashima T; Susaki EA; Ueda HR; Nangaku M
Kidney Int; 2020 May; 97(5):934-950. PubMed ID: 32171449
[TBL] [Abstract][Full Text] [Related]
3. Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease.
Uchida L; Tanaka T; Saito H; Sugahara M; Wakashima T; Fukui K; Nangaku M
Am J Physiol Renal Physiol; 2020 Feb; 318(2):F388-F401. PubMed ID: 31841388
[TBL] [Abstract][Full Text] [Related]
4. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
Fukui K; Shinozaki Y; Kobayashi H; Deai K; Yoshiuchi H; Matsui T; Matsuo A; Matsushita M; Tanaka T; Nangaku M
Eur J Pharmacol; 2019 Sep; 859():172532. PubMed ID: 31301309
[TBL] [Abstract][Full Text] [Related]
5. Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence.
Fujikawa R; Nagao Y; Fujioka M; Akizawa T
Ther Apher Dial; 2022 Aug; 26(4):679-693. PubMed ID: 35218616
[TBL] [Abstract][Full Text] [Related]
6. Prolyl hydroxylase inhibition protects the kidneys from ischemia via upregulation of glycogen storage.
Ito M; Tanaka T; Ishii T; Wakashima T; Fukui K; Nangaku M
Kidney Int; 2020 Apr; 97(4):687-701. PubMed ID: 32033782
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of prolyl hydroxylase domain (PHD) by JTZ-951 reduces obesity-related diseases in the liver, white adipose tissue, and kidney in mice with a high-fat diet.
Saito H; Tanaka T; Sugahara M; Tanaka S; Fukui K; Wakashima T; Nangaku M
Lab Invest; 2019 Jul; 99(8):1217-1232. PubMed ID: 30952940
[TBL] [Abstract][Full Text] [Related]
8. Enarodustat: First Approval.
Markham A
Drugs; 2021 Jan; 81(1):169-174. PubMed ID: 33320297
[TBL] [Abstract][Full Text] [Related]
9. Enarodustat to treat anemia in chronic kidney disease.
Fukui K; Tanaka T; Nangaku M
Drugs Today (Barc); 2021 Aug; 57(8):491-497. PubMed ID: 34405206
[TBL] [Abstract][Full Text] [Related]
10. JTZ-951, an HIF prolyl hydroxylase inhibitor, suppresses renal interstitial fibroblast transformation and expression of fibrosis-related factors.
Wakashima T; Tanaka T; Fukui K; Komoda Y; Shinozaki Y; Kobayashi H; Matsuo A; Nangaku M
Am J Physiol Renal Physiol; 2020 Jan; 318(1):F14-F24. PubMed ID: 31630548
[TBL] [Abstract][Full Text] [Related]
11. JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, improves iron utilization and anemia of inflammation: Comparative study against recombinant erythropoietin in rat.
Shinozaki Y; Fukui K; Kobayashi H; Yoshiuchi H; Matsuo A; Matsushita M
Eur J Pharmacol; 2021 May; 898():173990. PubMed ID: 33657422
[TBL] [Abstract][Full Text] [Related]
12. Effects of CP-900691, a novel peroxisome proliferator-activated receptor α, agonist on diabetic nephropathy in the BTBR ob/ob mouse.
Askari B; Wietecha T; Hudkins KL; Fox EJ; O'Brien KD; Kim J; Nguyen TQ; Alpers CE
Lab Invest; 2014 Aug; 94(8):851-62. PubMed ID: 24955894
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of prolyl hydroxylases increases hepatic insulin and decreases glucagon sensitivity by an HIF-2α-dependent mechanism.
Riopel M; Moon JS; Bandyopadhyay GK; You S; Lam K; Liu X; Kisseleva T; Brenner D; Lee YS
Mol Metab; 2020 Nov; 41():101039. PubMed ID: 32534258
[TBL] [Abstract][Full Text] [Related]
14. A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial.
Akizawa T; Nangaku M; Yamaguchi T; Arai M; Koretomo R; Matsui A; Hirakata H
Am J Nephrol; 2019; 49(2):165-174. PubMed ID: 30699415
[TBL] [Abstract][Full Text] [Related]
15. DMOG, a Prolyl Hydroxylase Inhibitor, Increases Hemoglobin Levels without Exacerbating Hypertension and Renal Injury in Salt-Sensitive Hypertensive Rats.
Kato S; Takahashi T; Miyata N; Roman RJ
J Pharmacol Exp Ther; 2020 Feb; 372(2):166-174. PubMed ID: 31801803
[TBL] [Abstract][Full Text] [Related]
16. Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial.
Akizawa T; Nangaku M; Yamaguchi T; Arai M; Koretomo R; Maeda K; Miyazawa Y; Hirakata H
Nephron; 2019; 143(2):77-85. PubMed ID: 31117088
[TBL] [Abstract][Full Text] [Related]
17. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Carcinogenic Potential of Enarodustat (JTZ-951), a Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor, in 26-Week Tg.rasH2 Mouse Study and 2-Year Sprague-Dawley Rat Study.
Kemmochi Y; Toyoda K; Ishida T; Yasui Y; Shoda T
Int J Toxicol; 2023 Dec; 42(6):489-503. PubMed ID: 37480334
[TBL] [Abstract][Full Text] [Related]
19. The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction.
Nakai T; Saigusa D; Kato K; Fukuuchi T; Koshiba S; Yamamoto M; Suzuki N
Life Sci; 2024 Jun; 346():122641. PubMed ID: 38614299
[TBL] [Abstract][Full Text] [Related]
20. Prolyl hydroxylase inhibitors: a breath of fresh air for diabetic kidney disease?
Forbes JM
Kidney Int; 2020 May; 97(5):855-857. PubMed ID: 32331596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
